Reports Q1 revenue $921K vs. $354K last year… We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need and fill a void in the market, which has the potential to increase value for our stockholders. We are focused on several areas that we believe will have a substantial impact on our growth and product adoption. Many of these areas of focus have begun showing positive results, as reflected in our most recent quarterly financial results. Our products continue to deliver impressive results with high patient satisfaction, with no demonstrated adverse events. We are also investing in sales improvement and long-term opportunities with all of our products…
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAOV:
- NanoVibronix in distribution pact with VA supplier CB Medical for UroShield
- NanoVibronix Inc Highlights 2023 Performance and Updates
- NanoVibronix issues letter to shareholders
- NanoVibronix Enhances Products with Veranex Partnership
- NanoVibronix to assist Veranex to develop UroShield and PainShield products
Questions or Comments about the article? Write to editor@tipranks.com